Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Faster heart attack diagnosis put to the test in 28,000-Person trial

NCT ID NCT07727135

Diagnosis Sponsor: Herlev and Gentofte Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This trial compares two blood-test strategies for diagnosing heart attacks in people with chest pain: the standard approach of testing at arrival and again 3 hours later, versus an accelerated approach testing at arrival and again after just 1 hour. The goal is to see whether the faster method is as safe while allowing patients to leave the hospital sooner. The study involves 28,000 adults at hospitals across Denmark.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high-sensitivity cardiac troponin blood test
What this could lead to
If the 1-hour strategy proves safe, it could allow faster diagnosis and shorter hospital stays for millions of people with chest pain.
What could go wrong
The 1-hour test might miss some heart attacks that the 3-hour test would catch, potentially increasing risk after discharge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (≥18 years) presenting with suspected acute coronary syndrome (ACS) with a clinical indication for high-sensitivity cardiac troponin testing Exclusion Criteria: * Age \<18 years. * ST-segment elevation myocardial infarction (STEMI) identified on the presenting electrocardiogram and requiring immediate reperfusion therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease acute are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome cardiovascular disorder coronary artery disorder intermediate coronary syndrome myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease acute Cardiovascular diseases Coronary artery disease Coronary syndrome, acute Myocardial infarction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aalborg University Hospital

    Aalborg, 9000, Denmark

  • Amager & Hvidovre Hospital

    Hvidovre, 2650, Denmark

  • Bispebjerg & Frederiksberg Hospital

    Bispebjerg, 2400, Denmark

  • Central Jutland Regional Hospital (Viborg Hospital & Silkeborg Hospital)

    Viborg, 8800, Denmark

  • Esbjerg og Grindsted Sygehus

    Esbjerg, 6700, Denmark

  • Gødstrup Regional Hospital

    Gødstrup, 7400, Denmark

  • Herlev & Gentofte Hospital

    Herlev, 2730, Denmark

  • Nordsjællands Hospital

    Hillerød, 3400, Denmark

  • Nykøbing Falster County Hospital

    Nykøbing Falster, 4800, Denmark

  • Odense University Hospital

    Odense, 5000, Denmark

  • Svendborg Hospital

    Svendborg, 5700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.